Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Intec Pharma Ltd. (NTEC) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/20/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
12/19/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Intec Pharma Publishes Letter to Shareholders"
12/06/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma to Continue Development Collaboration to Next Phase"
11/27/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6K",
"Notice and Proxy statement for the Special General Meeting of Shareholders of the Company to be held on December 20, 2018",
"Proxy card for the Special General Meeting of Shareholders of the Company to be held on December 20, 2018"
11/09/2018 6-K Quarterly results
Docs: "FORM 6-K",
"Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update",
"Unaudited Condensed Interim Financial Information for the Period Ended September 30, 2018",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operation for the Period Ended September 30, 2018"
10/22/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Intec Pharma Completes Enrollment of Pivotal Phase 3 Clinical Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson’ s Disease Patients"
09/25/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma to Present Multiple Posters at International Congress of Parkinson’ s and Movement Disorder Society JERUSALEM – Intec Pharma Ltd. today announces that three posters in support of the Company’ s Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa , will be presented at the upcoming International Congress of Parkinson’ s and Movement Disorder Society being held from October 5-9, 2018 in Hong Kong. “We are particularly pleased to have several posters at this important medical meeting discussing our Phase 3 clinical development program for AP-CD/LD as a potential best-in-class levodopa therapy for advanced Parkinson’ s disease patients,” stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “We believe these poster..."
09/20/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Intec Pharma to Participate at Upcoming Investment Conferences JERUSALEM – Intec Pharma Ltd. today announces that Company management will participate at the following upcoming investment conferences."
08/15/2018 6-K Quarterly results
Docs: "6-K",
"Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update",
"Unaudited Condensed Consolidated Interim Financial Information for the Period Ended June 30, 2018",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operation for the Period Ended June 30, 2018"
06/29/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma Appoints William Bradley Hayes to Board of Directors"
06/28/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/31/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6K",
"Intec Pharma to Present at Jefferies 2018 Healthcare Conference JERUSALEM – Intec Pharma Ltd. today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 – 8, 2018 in New York City. Jeffrey A. Meckler, Intec Pharma’ s Vice Chairman and Chief Executive Officer, will present a corporate overview on June 7th at 2:30 p.m. Eastern time. Mr. Meckler’ s presentation will be webcast live and will be accessible through the Events section of Intec Pharma’ s website, where it will also be archived for a period of time. About Intec Pharma Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’ s Accordion Pill is an oral dr..."
05/23/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Notice and Proxy statement for the Annual General Meeting of Shareholders of the Company to be held on June 28, 2018",
"Notice and Proxy statement for the Annual General Meeting of Shareholders of the Company to be held on June 28, 2018",
"Proxy card for the Annual General Meeting of Shareholders of the Company to be held on June 28, 2018"
05/11/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
04/24/2018 6-K Quarterly results
04/13/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Press release"
04/13/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6K",
"Underwriting Agreement, by and between the Company and Oppenheimer & Co. Inc., as representative of the several underwriters named therein",
"Opinion of Meitar Liquornik Geva Leshem Tal, Law Offices, Israeli Counsel to the Company"
04/11/2018 6-K Quarterly results
04/10/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Press Release"
04/04/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting"
04/03/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6K",
"Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson’ s Disease"
03/26/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6K",
"###"
03/12/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson’ s Disease"
03/09/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"INTEC PHARMA LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION December 31 2016 2017 U.S. dollars in thousands Assets CURRENT ASSETS: Cash and cash equivalents 16,376 53,324 Financial assets at fair value through profit or loss 1,852 1,825 Restricted bank deposits 62 69 Other receivables 2,384 1,125 20,674 56,343 NON-CURRENT ASSETS - Property and equipment 4,047 8,206 TOTAL ASSETS 24,721 64,549 Liabilities and equity CURRENT LIABILITIES - Accounts payable and accruals: Trade 1,152 1,854 Other 768 3,893 1,920 5,747 NON-CURRENT LIABILITIES - Derivative financial instruments 97 — COMMITMENTS AND CONTINGENT LIABILITIES TOTAL LIABILITIES 2,017 5,747 EQUITY: Ordinary shares 727 727 Share premium 84,980 148,968 Currency translation differences Accumulated deficit TOTAL EQUITY 22,704 58,802 TOT..."
03/05/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Intec Pharma, Ltd. To Present at Four Investor Conferences in March"
01/31/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer"
01/08/2018 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma Announces Development Collaboration with Global Pharmaceutical Company JERUSALEM – Intec Pharma Ltd. , a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals to explore using the Accordion Pill platform for a proprietary Novartis compound. The details of the therapeutic area or specific compound were not released. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill™ technology. “We are delighted to work with Novartis in ..."
01/03/2018 6-K Quarterly results
12/11/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
11/15/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"INTEC PHARMA LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION December 31, 2016 September 30, 2017 U.S. dollars in thousands Assets CURRENT ASSETS: Cash and cash equivalents 16,376 62,977 Financial assets at fair value through profit or loss 1,852 1,766 Restricted bank deposits 62 68 Other receivables 2,384 1,333 20,674 66,144 NON-CURRENT ASSETS - Property and equipment 4,047 5,902 TOTAL ASSETS 24,721 72,046 Liabilities and equity CURRENT LIABILITIES - Accounts payable and accruals: Trade 1,152 833 Other 768 2,490 1,920 3,323 NON-CURRENT LIABILITIES - Derivative financial instruments 97 — COMMITMENTS AND CONTINGENT LIABILITIES TOTAL LIABILITIES 2,017 3,323 EQUITY: Ordinary shares 727 727 Share premium 84,980 148,942 Currency translation differences Accumulated deficit ...",
"Unaudited Condensed Interim Financial Information for the Period Ended September 30, 2017",
"Management’ s Discussion and Analysis of Financial Condition and Results of Operation for the Period Ended September 30, 2017"
11/08/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Intec Pharma Ltd. To Present at the Jefferies 2017 London Healthcare Conference JERUSALEM, November 8, 2017 -- Intec Pharma Ltd. , a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Jeffrey Meckler, Chief Executive Officer, will provide a corporate overview at the Jefferies 2017 London Healthcare Conference, taking place November 15-16 at the Waldorf Hilton in London, England."
11/06/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Notice and Proxy Statement for the Annual General Meeting of Shareholders of the Company to be held on December 11, 2017",
"Proxy Card for the Annual General Meeting of Shareholders of the Company to be held on December 11, 2017"
11/01/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Convenience Translation from Hebrew of Notice of Annual General Meeting of Shareholders",
"Intec Pharma Ltd. Announces Changes to Its Board of Directors JERUSALEM – Intec Pharma Ltd. , a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Mr. Zvi Joseph, founder and Mr. Giora Carni, former CEO of Intec Pharma, will step down from their roles as Directors on the Board of Intec Pharma, and plan to serve as advisors to the Company going forward. “Zvi and Giora have been instrumental in the founding and early development of the Company, and we are pleased that they are remaining on as trusted advisors. We thank them for their vision and years of dedicated service that have been instrumental in bringing Intec to this critical point,” said John Kozarich, Chairman of the Board of I..."
10/26/2017 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Intec Pharma Names Walt Linscott as Chief Administrative Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy